ArticleFrontiers in oncology2021

Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents.

Zi-Kun Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.